Drugs / [212Pb]Pb-MP0712
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07278479 | May 2026 → Sep 2028 expected | digestive system neuroendocrine neoplasm, pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma, urinary bladder cancer | Molecular Partners AG | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [212Pb]Pb-MP0712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07278479 ↗ |